Minireviews
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2020; 12(2): 173-181
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.173
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G Papavassiliou, Michalis V Karamouzis
Panagiotis Sarantis, Evangelos Koustas, Athanasios G Papavassiliou, Michalis V Karamouzis, Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece
Adriana Papadimitropoulou, Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens 11527, Greece
Michalis V Karamouzis, First Department of Internal Medicine, “Laiko” General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece
Author contributions: Sarantis P, Koustas E and Papadimitropoulou A have equal contribution; Sarantis P, Koustas E and Papadimitropoulou A made substantial contributions to acquisition, analysis and interpretation of data; Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG and Karamouzis MV made substantial contributions in the conception, design and interpretation of the data; Papavassiliou AG and Karamouzis MV made substantial contributions in drafting the manuscript and revising it critically for important intellectual content.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Michalis V Karamouzis, MD, PhD, Associate Professor, Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75, M. Asias Street, Athens 11527, Greece. mkaramouz@med.uoa.gr
Received: March 29, 2019
Peer-review started: April 3, 2019
First decision: November 11, 2019
Revised: November 28, 2019
Accepted: December 13, 2019
Article in press: December 13, 2019
Published online: February 15, 2020
Core Tip

Core tip: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies. Treatments such as surgery, radiation, and chemotherapy have limited efficacy due to the extensive heterogeneity of genetic mutations and the dense stromal environment, among other causes. In recent years, immunotherapy has been successfully applied in the treatment of various types of cancers, and immunotherapy combined with the above treatments could create more favorable conditions for the fight against PDAC.